Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Magnum Ice Cream Company N.V. Ordinary Shares (MICC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance

The Magnum Ice Cream Company N.V. Ordinary SharesTrade
Maravai LifeSciences Holdings Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

The Magnum Ice Cream Company N.V. Ordinary Shares vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? The Magnum Ice Cream Company N.V. Ordinary Shares trades at $17.92 (market cap $10.72B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: The Magnum Ice Cream Company N.V. Ordinary Shares is far larger — about 11× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (4,325,710 versus 1,309,650). Which is the better fit depends on your goals — on Pluang, investors hold The Magnum Ice Cream Company N.V. Ordinary Shares for 0 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.

MICCMRVI
Market Cap
$10.72B$972.90M
Volume
1,309,6504,325,710
Sector
Consumer StaplesHealth
52-Week High
$20.42$9.00
52-Week Low
$13.06$2.83
Typical Hold Time
0 Days0 Days
Enterprise Value
$14.14B$1.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Magnum Ice Cream Company N.V. Ordinary Shares

No Aura AI signal available yet.

Maravai LifeSciences Holdings Inc. Class A Common Stock

Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.

The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MICC
100% Buy0% Sell
Avg holding period · 0 Days
MRVI
100% Buy0% Sell
Avg holding period · 0 Days

About The Magnum Ice Cream Company N.V. Ordinary Shares

The Magnum Ice Cream Company N.V. manufactures and sells ice cream and frozen desserts through brands including Magnum, Ben & Jerry's, Wall's, and Cornetto, distributing across roughly 80 countries.

Read more on MICC →

About Maravai LifeSciences Holdings Inc. Class A Common Stock

Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.

Read more on MRVI →